Molecular Insight Pharmaceuticals, Inc. · Cambridge, MA United States (UTP NASDAQ: MIPI)
| 160 2nd St. | Phone: 617-492-5554 |
| Cambridge, MA | Fax: 617-492-5664 |
| 02142 | |
| United States | 
Map This Company |
Molecular Insight Pharmaceuticals, Inc. Rankings
More Companies in These Related Industries: Market ResearchCompany Description
Molecular Insight Pharmaceuticals (MIP) is working to make cancer invisible. The development-stage company is focused on making molecular imaging and radiotherapeutic products that help diagnose and treat various diseases by combining radiation therapy with biochemical and molecular science. MIP is focused on oncology and has diagnostic and radiotherapeutic candidates under development in areas including prostate cancer, neuroendocrine cancers, and metastatic melanoma. It is also developing a cardiovascular diagnostic imaging agent that highlights distressed areas of the heart in a patient experiencing chest pain. The company emerged from Chapter 11 bankruptcy protection in 2011.
Molecular Insight Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Private - UTP NASDAQ: MIPI Headquarters |
|---|---|
| Fiscal Year-End | December |
| Employees | 81 |
Executives
18 executives listed for Molecular Insight Pharmaceuticals, Inc.'s Cambridge, MA location.
| Chairman | Joseph Limber | |
|---|---|---|
| President, Chief Restructuring Officer, and Director | Harry Stylli | |
| Interim EVP and Interim CFO | Mark Attarian |